NCT04478019

SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding

Role of NaSo-oropHaryngeal Antiseptic dEcolonizaiton to Reduce Covid-19 Viral Shedding and Disease Transmission: SHIELD Study

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 245 (actual)
• Sponsor: University of Wisconsin, Madison · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Essential workers in positions with increased likelihood of exposure to SARS-CoC-2 will be most impacted by the proposed project. Evidence has shown that the SARS-CoV-2 novel coronavirus is easily transmissable through close contact between individuals, especially during aerosol-generating procedures such as intubation of patients. The intervention proposed in this study (nasal and oral decontamination with povidone-iodine and chlorhexidine, respectively) presents an opportunity for a safe, effective, and feasible treatment to decontaminate the primary entry points for SARS-CoV-2. As such, the intervention to be studied in this project may protect healthcare and other essential workers by preventing transmission of SARS-CoV-2 from patients to healthcare workers, as well as the general public to essential worker,. and thus reducing the incidence of COVID-19 in these workers.

Conditions

• COVID-19
• SARS-CoV 2

Interventions

Type	Name	Description
DRUG	10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse	2 swab sticks of 10% povidone-iodine in each nares and 0.12% CHG oral rinse

Timeline

• Start date: 2020-07-07
• Primary completion: 2022-06-30
• Completion: 2022-06-30
• First posted: 2020-07-20
• Last updated: 2022-07-14

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study